Second Window Indocyanine Green for All Nervous System Tumors
Status:
Not yet recruiting
Trial end date:
2025-02-15
Target enrollment:
Participant gender:
Summary
The study is being conducted to determine if a same-day, low-dose intravenous (into a vein)
injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging
system can be a useful tool in identifying and differentiating tumor tissue from normal
tissues.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania